Bipolar Depression
Conditions
Keywords
Mood Regulating Circuit, Lithium, fMRI
Brief summary
The purpose of this study is to find out what parts of the brain have increased or decreased activity with individuals who have bipolar disorder and how medicine changes this activity in bipolar subjects. Another purpose of this study is to compare data obtained from bipolar depressed subjects with data obtained from healthy subjects. In this study we will measure activity in different parts of the brain, while participants see pictures, using Magnetic Resonance Imaging (MRI) scan. We will do two MRI scans with each subject before and after treatment for eight weeks with a standard bipolar disorder medication called lithium.
Detailed description
Aim 1: Our first aim is to use a novel fMRI experimental paradigm to investigate the pathophysiology of bipolar disorder (BD) in terms of the strength of connectivity (as measured by LFBF correlations) between the different emotion regulating areas of the brain rather than in terms of increase or decrease in localized brain activity. Specific Aim 2: Our second aim is to investigate whether lithium works by altering the connectivity of areas of the brain implicated in the pathophysiology of BD, thereby leading to changes in the abnormal positive or negative emotional reactions to the environment seen in mania and depression respectively. Specific Aim 3: Out third aim is to investigate whether patients with the s/s or s/L alleles of the 5-HTTLPR polymorphism will have greater amygdalar activation and decreased cortico-amygdala connectivity compared to patients with L/L genotype. We will also investigate whether lithium treatment differentially affects these fMRI measures in the s/s or s/L and L/L genotypes. Methods: We will study unmedicated subjects satisfying DSM-IV criteria for Bipolar Disorder current episode depressed or hypomanic/manic or who are euthymic. Subjects will undergo fMRI before and after 8 weeks of treatment with lithium a mood stabilizer that is known to be effective in both phases of BD. Healthy subjects will have a scan at baseline and after 8 weeks but will not be treated with any medication. We will also test for the serotonin transporter gene (the gene that controls the availability of a chemical called serotonin in the brain), which has been shown to effect how lithium works.
Interventions
DRUGLithium
starting dose 600 mg increase as tolerated
Sponsors
Indiana University School of Medicine
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
Inclusion criteria for Bipolar Subjects * Ages 18-60 years and able to give voluntary informed consent. * Satisfy criteria for Bipolar Depression using the Structured Clinical Interview for Diagnostic and Statistical Manual -4th edition (DSM-IV) (SCID-IV). * Bipolar depressed subjects: 25-item Hamilton Depression Rating Scale (HDRS) score \> 18.Young Mania Rating Score (YMRS)\<10. * Bipolar hypomanic/manic subjects will have a YMRS score\>12 and a 25-item HDRS score\<10. * Bipolar Euthymic subjects will have YMRS score \< 10 and HDRS score \< 10 and would have been euthymic for \> 14 days. * Subjects will be drug and medication free and would have no significant history of medical or neurological illness. * Satisfy criteria to undergo an MRI scan based on MRI screening questionnaire * Able to be managed as outpatients for initial assessment and during treatment as ascertained by the following: * Symptoms not worsening by more than 10 points on either the HDRS or the YMRS during the course of the study. * No danger to self or others. * No psychotic symptoms. Inclusion criteria for Healthy Subjects: * Ages 18-60 years and able to give voluntary informed consent. * No history of psychiatric illness or substance abuse or dependence as assessed by SCID for non-patients (SCID-NP). * No significant family history of psychiatric or neurological illness. * Not currently taking any prescription or centrally acting medications. * No serious medical or neurological illness as assessed by history, physical examination and laboratory examination including CBC and blood chemistry.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparative activation of amygdala and cortico-amydalar connectivity as measured by fMRI taken at baseline and eight weeks from baseline | 07-03 to 3-07 |
| Improvement of scores on Hamilton Depression Rating Scale given weekly for eight weeks | 07-03 to 3-07 |
Secondary
| Measure | Time frame |
|---|---|
| Improvement as measured by the Clinical Global Impression Severity and Improvement Scales given weekly for eight weeks | 07-03 to 3-07 |
| Improvement as measured by the Brief Psychiatric Rating Scale given weekly for eight weeks | 07-03 to 3-07 |
Countries
United States
Outcome results
None listed